TY - JOUR
T1 - Correction
T2 - Targeting of PYK2 synergizes with EGFR antagonists in basal-like TNBC and circumvents HER3-associated resistance via the NEDD4–NDRG1 axis (Cancer Research (2017) 77 (86–99) DOI: 10.1158/0008-5472.CAN-16-1797)
AU - Verma, Nandini
AU - Muller, Anna Katharina
AU - Kothari, Charu
AU - Panayotopoulou, Effrosini
AU - Kedan, Amir
AU - Selitrennik, Michael
AU - Mills, Gordon B.
AU - Nguyen, Lan K.
AU - Shin, Sungyoung
AU - Karn, Thomas
AU - Holtrich, Uwe
AU - Lev, Sima
N1 - Publisher Copyright:
© 2020 American Association for Cancer Research.
PY - 2020/1/15
Y1 - 2020/1/15
N2 - In the original version of this article (1), two instances of inadvertent duplication of crystal violet staining images occurred in Fig. 1D (control shRNA conditions in MDA-MB-468 and BT-20) and in Fig. 1F (0 mmol/L gefitinib control conditions in MDA-468 and BT-20). In addition, the same set of STAT3 Western blot bands was inadvertently duplicated in Fig. 3A (BT-20 and HCC1937). These errors have been corrected in the latest online HTML and PDF versions of the article. The authors regret these errors.
AB - In the original version of this article (1), two instances of inadvertent duplication of crystal violet staining images occurred in Fig. 1D (control shRNA conditions in MDA-MB-468 and BT-20) and in Fig. 1F (0 mmol/L gefitinib control conditions in MDA-468 and BT-20). In addition, the same set of STAT3 Western blot bands was inadvertently duplicated in Fig. 3A (BT-20 and HCC1937). These errors have been corrected in the latest online HTML and PDF versions of the article. The authors regret these errors.
UR - http://www.scopus.com/inward/record.url?scp=85077820145&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85077820145&partnerID=8YFLogxK
U2 - 10.1158/0008-5472.CAN-19-3573
DO - 10.1158/0008-5472.CAN-19-3573
M3 - Comment/debate
C2 - 31941679
AN - SCOPUS:85077820145
SN - 0008-5472
VL - 80
SP - 362
JO - Cancer Research
JF - Cancer Research
IS - 2
ER -